We are live on ! Find out more
AA

ALPS Advisors Portfolio holdings

AUM $21.3B
1-Year Est. Return 21.71%
This Fund
S&P 500
This Quarter Est. Return
-0.12%
1 Year Est. Return
+21.71%
3 Year Est. Return
+77.63%
5 Year Est. Return
+121.1%
10 Year Est. Return
+198.29%
AUM
$12.8B
AUM Growth
-$14.9M
Cap. Flow
+$218M
Cap. Flow %
1.7%
Top 10 Hldgs %
47.35%
Holding
887
New
65
Increased
163
Reduced
583
Closed
74

Top Sells

Rank Stock Value
1
QCOM icon
Qualcomm
QCOM
+$37M
2
EIX icon
Edison International
EIX
+$36.3M
3
ETR icon
Entergy
ETR
+$35.8M
4
PKG icon
Packaging Corp of America
PKG
+$35.3M
5
NWL icon
Newell Brands
NWL
+$35.1M

Sector Composition

Rank Sector Weight
1 Energy 62.99%
2 Financials 8.19%
3 Healthcare 3.89%
4 Consumer Discretionary 3.19%
5 Technology 2.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
V icon
176
Visa
V
$677B
$3.85M 0.03%
20,472
-530
-3% -$95.5K
HD icon
177
Home Depot
HD
$332B
$3.84M 0.03%
17,586
-895
-5% -$203K
GOOGL icon
178
Alphabet (Google) Class A
GOOGL
$3.91T
$3.82M 0.03%
57,060
-3,220
-5% -$208K
ENOV icon
179
Enovis
ENOV
$1.56B
$3.7M 0.03%
59,030
-67,570
-53% -$3.82M
LGND icon
180
Ligand Pharmaceuticals
LGND
$6.02B
$3.69M 0.03%
56,669
-4,130
-7% -$276K
CVX icon
181
Chevron
CVX
$388B
$3.67M 0.03%
30,481
-1,374
-4% -$162K
PTLA
182
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$3.67M 0.03%
+153,713
New +$4.24M
NMFC icon
183
New Mountain Finance
NMFC
$646M
$3.66M 0.03%
266,100
-23,500
-8% -$318K
PRNB
184
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$3.61M 0.03%
65,958
+18,192
+38% +$679K
ZYME icon
185
Zymeworks
ZYME
$1.68B
$3.6M 0.03%
+79,257
New +$2.88M
GOOG icon
186
Alphabet (Google) Class C
GOOG
$3.9T
$3.49M 0.03%
52,220
-3,040
-6% -$196K
TERP
187
DELISTED
TerraForm Power, Inc
TERP
$3.38M 0.03%
219,756
+72,679
+49% +$1.17M
SWTX
188
DELISTED
SpringWorks Therapeutics
SWTX
$3.33M 0.03%
+86,603
New +$2.03M
AKCA
189
DELISTED
Akcea Therapeutics Inc
AKCA
$3.2M 0.03%
189,124
+3,626
+2% +$67.5K
CNST
190
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$3.18M 0.02%
67,578
+16,117
+31% +$465K
PG icon
191
Procter & Gamble
PG
$343B
$3.06M 0.02%
24,525
-1,189
-5% -$145K
DRNA
192
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$3.04M 0.02%
137,919
+1,615
+1% +$32.5K
QNCX icon
193
Quince Therapeutics
QNCX
$17.5M
$3.03M 0.02%
+270
New +$1.63M
NKE icon
194
Nike
NKE
$61.9B
$2.99M 0.02%
29,491
-1,523
-5% -$144K
FATE icon
195
Fate Therapeutics
FATE
$281M
$2.98M 0.02%
152,157
+21,771
+17% +$346K
BLDP
196
Ballard Power Systems
BLDP
$874M
$2.89M 0.02%
402,072
+79,462
+25% +$485K
BA icon
197
Boeing
BA
$165B
$2.84M 0.02%
8,726
-450
-5% -$159K
SCHP icon
198
Schwab US TIPS ETF
SCHP
$16.3B
$2.83M 0.02%
100,072
+50
+0% +$1.42K
MDGL icon
199
Madrigal Pharmaceuticals
MDGL
$12.6B
$2.83M 0.02%
31,020
+263
+0.9% +$25.5K
RUN icon
200
Sunrun
RUN
$2.37B
$2.82M 0.02%
203,920
-17,525
-8% -$261K

Similar funds

ALPS Advisors's Q4 2019 Portfolio in Review

As of Q4 2019, ALPS Advisors held 887 positions worth $12.8B, down 0.12% from $12.8B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

ALPS Advisors's Q4 2019 filing shows 65 new, 163 increased, 583 reduced and 74 closed positions. Its largest new stake was CenterPoint Energy: 1,338,870 shares worth $36.5M. The largest sale was Qualcomm, an estimated $37M.

By sector, the portfolio is most concentrated in Energy at 63% of assets, down from 65% a quarter earlier, followed by Financials and Healthcare.

  • ALPS Advisors's largest Q4 2019 buy was CenterPoint Energy: 1,338,870 shares worth $36.5M.
  • ALPS Advisors added most to PHILLIPS 66 PARTNERS LP in Q4 2019, an estimated $102M increase.
  • ALPS Advisors's biggest Q4 2019 reduction was Qualcomm, cutting an estimated $37M.
  • ALPS Advisors fully exited Edison International in Q4 2019, selling an estimated $36.3M.
  • ALPS Advisors's ten largest holdings make up 47% of its $12.8B portfolio in Q4 2019.
  • ALPS Advisors opened 65 new positions and closed 74 in Q4 2019.
  • ALPS Advisors's portfolio value fell 0.12% quarter-over-quarter to $12.8B.

Based on ALPS Advisors's 13F filing for Q4 2019, filed 7 Feb 2020.